Search research articles
Contact Us
Filters
Showing results (201-210 of 314) with videos related to
Page
of 32
Sort By:
Molecular Microbiology
|
January 14, 1998
Helicobacter pylori toxin VacA induces vacuole formation by acting in the cell cytosol
M de Bernard, B Arico, E Papini, et al.
Infection and Immunity
|
February 1, 1991
Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment
L Nencioni, G Volpini, S Peppoloni, et al.
Infection and Immunity
|
May 1, 1994
Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing
A di Tommaso, M T de Magistris, M Bugnoli, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 11, 1994
Cellular vacuoles induced by Helicobacter pylori originate from late endosomal compartments
E Papini, M de Bernard, E Milia, et al.
Infection and Immunity
|
July 23, 1998
Binding of the Helicobacter pylori vacuolating cytotoxin to target cells
P Massari, R Manetti, D Burroni, et al.
Infection and Immunity
|
March 1, 1992
Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule
I Marsili, M Pizza, F Giovannoni, et al.
Immunobiology
|
February 1, 1992
Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin
R Rappuoli, M Pizza, M T De Magistris, et al.
Infection and Immunity
|
January 1, 1995
Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin
Z Xiang, S Censini, P F Bayeli, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 28, 1995
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
G Douce, C Turcotte, I Cropley, et al.
Vaccine
|
April 20, 2013
Strategic priorities for respiratory syncytial virus (RSV) vaccine development
L J Anderson, P R Dormitzer, D J Nokes, et al.
Page
of 32
Search research articles
Search
Showing results (201-210 of 314) with videos related to
Sort By:
Page
of 32
Molecular Microbiology
|
January 14, 1998
Helicobacter pylori toxin VacA induces vacuole formation by acting in the cell cytosol
M de Bernard, B Arico, E Papini, et al.
Infection and Immunity
|
February 1, 1991
Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment
L Nencioni, G Volpini, S Peppoloni, et al.
Infection and Immunity
|
May 1, 1994
Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing
A di Tommaso, M T de Magistris, M Bugnoli, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
October 11, 1994
Cellular vacuoles induced by Helicobacter pylori originate from late endosomal compartments
E Papini, M de Bernard, E Milia, et al.
Infection and Immunity
|
July 23, 1998
Binding of the Helicobacter pylori vacuolating cytotoxin to target cells
P Massari, R Manetti, D Burroni, et al.
Infection and Immunity
|
March 1, 1992
Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule
I Marsili, M Pizza, F Giovannoni, et al.
Immunobiology
|
February 1, 1992
Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin
R Rappuoli, M Pizza, M T De Magistris, et al.
Infection and Immunity
|
January 1, 1995
Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin
Z Xiang, S Censini, P F Bayeli, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 28, 1995
Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
G Douce, C Turcotte, I Cropley, et al.
Vaccine
|
April 20, 2013
Strategic priorities for respiratory syncytial virus (RSV) vaccine development
L J Anderson, P R Dormitzer, D J Nokes, et al.
Page
of 32